Last reviewed · How we verify
Moderate to severe Crohn's disease and perianal disease and fistulizing disease — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Induction- PF-06480605 450 mg SC Q4W | induction-pf-06480605-450-mg-sc-q4w | Pfizer | small molecule | IL-17 receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Moderate to severe Crohn's disease and perianal disease and fistulizing disease
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Moderate to severe Crohn's disease and perianal disease and fistulizing disease:
- Moderate to severe Crohn's disease and perianal disease and fistulizing disease treatment updates — RSS
- Moderate to severe Crohn's disease and perianal disease and fistulizing disease treatment updates — Atom
- Moderate to severe Crohn's disease and perianal disease and fistulizing disease treatment updates — JSON
Cite this brief
Drug Landscape (2026). Moderate to severe Crohn's disease and perianal disease and fistulizing disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/moderate-to-severe-crohn-s-disease-and-perianal-disease-and-fistulizing-disease. Accessed 2026-06-10.
Related
- Moderate to severe Crohn's disease and perianal disease and fistulizing disease full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing